Home / Health / New Clues Emerge in Pancreatic Cancer Drug Resistance
New Clues Emerge in Pancreatic Cancer Drug Resistance
30 Sep
Summary
- Researchers are studying why pancreatic cancer stops responding to new drugs.
- Tumor cells surviving treatment appear to adapt and grow.
- Increased amounts of KRAS protein may allow cancer to evade medication.
Researchers are actively investigating why pancreatic cancer develops resistance to targeted drugs like daraxonrasib, a treatment that initially doubled survival rates for advanced cases. Despite its effectiveness, resistance typically emerges after about seven months, a common challenge with targeted cancer therapies.
Preliminary studies presented at a recent conference reveal that daraxonrasib rapidly reduces tumor cell count. However, the surviving cells exhibit changes, appearing more like chemotherapy-responsive cells, suggesting potential benefits from combination treatments.
Further analysis of blood and tumor biopsies indicates that over half of resistant cancers achieve this by overproducing the KRAS protein, which daraxonrasib aims to block. This finding raises questions about using multiple KRAS inhibitors concurrently, with numerous such drugs currently in clinical trials.
While some resistance mechanisms are still unclear, potentially involving non-genetic changes, ongoing research funded by leading foundations aims to develop therapies that overcome this evasion, with a long-term goal of achieving cures.
